Rapport Therapeutics, Inc.
RAPPUnited States
9 filed reports · 212 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
9 reports · Jun 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 7 | 1,033 | Jun 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 2 | 746 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 285 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 168 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 10, 2026 | 453 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 177 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 106 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 114 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 11, 2025 | 293 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 100 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 83 | Open |
Financial data
212 concepts · 1,779 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial209 concepts · 1,682 facts · Mar 2023 to Aug 2026
- Net income loss17 · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)17 · Mar 2023 to Jun 2026
- Allocated share based compensation expense16 · Jun 2023 to Jun 2026
- Cash and cash equivalents at carrying value16 · Jun 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations16 · Jun 2023 to Jun 2026
- Comprehensive income net of tax16 · Jun 2023 to Jun 2026
- Investment income interest16 · Jun 2023 to Jun 2026
- Net income loss available to common stockholders basic16 · Jun 2023 to Jun 2026
- Nonoperating income expense16 · Jun 2023 to Jun 2026
- Operating expenses (US GAAP)16 · Jun 2023 to Jun 2026
- Operating income loss16 · Jun 2023 to Jun 2026
- Research and development expense16 · Jun 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value15 · Mar 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect15 · Sep 2023 to Jun 2026
- Deferred offering costs15 · Jun 2023 to Jun 2026
- Depreciation depletion and amortization15 · Sep 2023 to Jun 2026
- Increase decrease in accounts payable15 · Sep 2023 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities15 · Sep 2023 to Jun 2026
- Increase decrease in other operating assets15 · Sep 2023 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets15 · Sep 2023 to Jun 2026
- Net cash provided by used in financing activities15 · Sep 2023 to Jun 2026
- Net cash provided by used in investing activities15 · Sep 2023 to Jun 2026
- Net cash provided by used in operating activities15 · Sep 2023 to Jun 2026
- Payments to acquire property plant and equipment15 · Sep 2023 to Jun 2026
Product3 concepts · 97 facts · Dec 2023 to Jun 2026
- Research and development expense52 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)33 · Dec 2023 to Dec 2025
- Selling general and administrative expense12 · Mar 2025 to Jun 2026
Segments
97 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service7 members · 97 facts
- Facility Related And Other15 · Dec 2023 to Jun 2026
- General And Administrative Personnel Related Costs Including Stock- Based Compensation15 · Dec 2023 to Jun 2026
- Professional And Consulting Costs15 · Dec 2023 to Jun 2026
- Other Costs13 · Dec 2023 to Jun 2026
- Preclinical Programs External Expenses13 · Dec 2023 to Jun 2026
- RAP219 Program External Expenses13 · Dec 2023 to Jun 2026
- Research And Development Personnel Related Costs Including Stock- Based Compensation13 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.